Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Helios CR Inc

Neither a doctor nor a teaching hospital

Research payments

$3,855,369

752 payments

Through program year 2025, Helios CR Inc is reported as receiving $3,855,369 in research payments, across 752 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $2,949,923 619
2024 Research $301,759 78
2023 Research $603,687 55

Breakdown

Who paid Research payments · program years 2023–2025
  1. Moderna TX, Inc. $2,479,369 435 payments
  2. GlaxoSmithKline, LLC. $633,034 60 payments
  3. Janssen Research & Development, LLC $282,367 59 payments
  4. Genentech, Inc. $141,094 25 payments
  5. Sumitomo Pharma America, Inc. $101,388 53 payments
  6. Jazz Pharmaceuticals Inc. $82,706 17 payments
  7. Pfizer Inc. $60,013 8 payments
  8. Hoffmann-La Roche Limited $30,176 24 payments
  9. Aesculap Biologics, LLC $22,155 8 payments
  10. Regeneron Pharmaceuticals, Inc. $13,328 60 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $1,669,815 164 payments
  2. A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ?60 Years of Age $273,124 102 payments
  3. A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults $271,415 35 payments
  4. A Phase III, Open-Label, Randomized, Controlled, Multi-Country Study T $264,016 19 payments
  5. A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes $169,504 64 payments
  6. A Phase 3, Open-Label, Randomized, Controlled, Multi Country Study to $150,415 16 payments
  7. Roche Cancer Screening Collection Study $141,094 25 payments
  8. A Phase 3, Randomized, Placebo-Controlled, Observer-Blind, Multi-Count $131,897 9 payments
  9. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $87,722 47 payments
  10. A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc $75,021 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record